Picture of Sanofi SA logo

SAN Sanofi SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

REG - Bank of NY Mel Corp Sanofi SA - Form 8.3 - Sanofi

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221201:nRSA3333Ia&default-theme=true

RNS Number : 3333I  Bank of New York Mellon Corp. (The)  01 December 2022

Ap27

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE

 

1.             KEY INFORMATION

 

 (a)   Full name of discloser                                                     The Bank of New York Mellon Corporation and its subsidiaries, 1. BNY Mellon
                                                                                  Service Kapitalanlage-Gesellschaft mbH, 2. Insight Investment Management
                                                                                  (Global) Limited, 3. The Bank of New York Mellon, 4. BNY Mellon Investment
                                                                                  Adviser, Inc., 5. Mellon Investments Corporation, 6. Newton Investment
                                                                                  Management Limited, 7. Newton Investment Management North America, LLC, 8.
                                                                                  Lockwood Advisors, Inc., 9. BNY Mellon Securities Corporation, 10. Pershing
                                                                                  LLC, 11. BNY Mellon Trust of Delaware, 12. BNY Mellon, National Association
 (b)   Owner or controller of interests and short positions disclosed, if         N/A
 different from 1(a)

 The naming of nominee or vehicle companies is insufficient. For a trust, the
 trustee(s), settlor and beneficiaries must be named.
 (c)   Name of offeror/offeree in relation to whose relevant securities this      Sanofi
 form relates

 Use a separate form for each offeror/offeree
 (d)   If an exempt fund manager connected with an offeror/offeree, state this    N/A
 and specify identity of offeror/offeree (Note 1)
 (e)   Date position held/dealing undertaken                                      30 November 2022

 For an opening position disclosure, state the latest practicable date prior to
 the disclosure
 (f)    In addition to the company in 1(c) above, is the discloser also           YES, we are reporting in respect to the Offeree Horizon Therapeutics plc and
 making disclosures in respect of any other party to the offer?                   Offeror Amgen Inc.

 If it is a cash offer or possible cash offer, state "N/A"

 

 

2.             INTERESTS AND SHORT POSITIONS

 

If there are interests and short positions to disclose in more than one class
of relevant securities of the offeror or offeree named in 1(c), copy table 2
for each additional class of relevant security.

 

Interests and short positions in the relevant securities of the offeror or
offeree to which the disclosure relates following the dealing (if any)

(Note 2)

 

 Class of relevant security                                              Ordinary Shares
 (Note 3)
                                                                         Interests          Short positions
                                                                         Number      %      Number    %
 (1)   Relevant securities owned and/or controlled                       10,976,049  0.87%
 (2)   Cash-settled derivatives                                                             18,000    0.001%
 (3)   Stock-settled derivatives (including options) and agreements to
 purchase/ sell
 Total                                                                   10,976,049  0.87%  18,000    0.001%

 

All interests and all short positions should be disclosed.

 

Details of options including rights to subscribe for new securities and any
open stock-settled derivative positions (including traded options), or
agreements to purchase or sell relevant securities, should be given on a
Supplemental Form 8.

 

3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
(Note 4)

 

Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)           Purchases and sales

 

 Class of relevant  Purchase/sale  Number of    Price per unit

security
securities  (Note 5)
 Ordinary Shares    Purchase       1,285        EUR 86.48

Ordinary Shares
Sale
3,822
EUR 86.48

Ordinary Shares
Purchase
14,163
EUR 86.48

Ordinary Shares
Sale
28,421
EUR 86.48

Ordinary Shares
Transfer In
309
N/A

Ordinary Shares
Transfer Out
3,196
N/A

Ordinary Shares
Sale
139
EUR 86.67

ADR
Purchase
319
USD 44.45

Ordinary Shares
Sale
6,108
EUR 85.98

ADR
Purchase
59
USD 44.72

ADR
Transfer Out
72
N/A

Purchase
294
USD 45.35
 ADR

                  Sale           6            USD 45.05
 ADR

                  Purchase       1,340        USD 45.35
 ADR

(b)           Cash-settled derivative transactions

 

 Class of   Product        Nature of dealing                                                            Number of     Price
 relevant   description    e.g. opening/ closing a long/ short position, increasing/ reducing a long/   reference     per unit
 security   e.g. CFD       short position                                                               securities    (Note 5)
                                                                                                        (Note 6)

 

(c)           Stock-settled derivative transactions (including options)

 

(i)            Writing, selling, purchasing or varying

 

 Class of    Product                  Writing, purchasing, selling, varying   Number        Exercise     Type         Expiry   Option
 relevant    description e.g. call    etc.                                    of
price per   e.g.         date     money
 security    option                                                           securities    unit         American,
paid/
                                                                              to which                   European              received per unit
                                                                              option
etc.
                                                                              relates
                                                                              (Note 6)

 

(ii)           Exercise

 

 Class of    Product        Exercising/   Number of    Exercise
 relevant    description    exercised     securities   price per
 security    e.g. call      against                    unit
             option                                    (Note 5)

 

(d)           Other dealings (including transactions in respect of new
securities) (Note 3)

 

 Class of    Nature of dealing      Details  Price per unit (if
 relevant    e.g. subscription,              applicable)
 security    conversion, exercise            (Note 5)

 

4.             OTHER INFORMATION

 

(a)           Indemnity and other dealing arrangements

 

 Details of any indemnity or option arrangement, or any agreement or
 understanding, formal or informal, relating to relevant securities which may
 be an inducement to deal or refrain from dealing entered into by the person
 making the disclosure and any party to the offer or any person acting in
 concert with a party to the offer.

 Irrevocable commitments and letters of intent should not be included. If there
 are no such agreements, arrangements or understandings, state "none"
  None

 

(b)           Agreements, arrangements or understandings relating to
options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person
 disclosing and any other person relating to the voting rights of any relevant
 securities under any option referred to on this form or relating to the voting
 rights or future acquisition or disposal of any relevant securities to which
 any derivative referred to on this form is referenced. If none, this should be
 stated.
  None

 

(c)           Attachments

 

 Is a Supplemental Form 8 attached?  NO

 

 Date of disclosure  01 December 2022
 Contact name        Andrew Weiser
 Telephone number    516-338-3752

 

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory
Information Service.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEDZMGZVMNGZZM

Recent news on Sanofi SA

See all news